Chris Cano

Chris Cano currently serves as Chief Operating Officer and Vice President of Business Development at TFF Pharmaceuticals, Inc. since September 2020 while also managing a consulting practice, C2 Strategic Solutions LLC, since January 2011, focusing on strategic planning, mergers and acquisitions, licensing, and corporate development. Previous roles include Vice President of Business Development at Aqua Pharmaceuticals, Director of Business Development at Duchesnay, and Associate Director of Business Development at Noven Pharmaceuticals. Chris's career includes significant achievements in corporate development, notably selling Nucryst Pharmaceuticals to Smith & Nephew and Barrier Therapeutics Inc. to Stiefel Labs. Chris holds an EMBA from Rider University and a BSBA in Finance from Villanova University, along with a foundational education from Don Bosco Prep.